抗体治療薬の分野は近年急速に発展しており、最もエキサイティングな開発の 1 つは、モノクローナル抗体から二重特異性抗体、そして新たに登場した四重特異性抗体への移行です。これらの新世代の抗体は、さまざまな疾患や状態に対して、より標的を絞った効果的な治療法となる可能性を秘めています。従来、モノクローナル抗体は治療薬の開発に使用されてきました。これらは、単一の抗原またはタンパク質を標的にするように設計された抗体であり、がん、自己免疫疾患、感染症など、さまざまな疾患の治療に有効です。
目次
1. Introduction to Tetraspecific Antibodies
1.1 Clinical Overview
1.2 History and Development
2. Tetraspecific Antibodies Mechanism Of Action
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells and Target Cells Closer
3. Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication and Phase
3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Phase
4. Global Tetraspecific Ongoing Clinical Trials Insight
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-II
5. Tetraspecific Antibodies Proprietary Technologies By Company
5.1 Available Proprietary Platforms
5.2 Potential Proprietary Platforms
6. Current Clinical Development and Future Commercialization Outlook
6.1 Current Scenario
6.2 Future Market Commercialization Outlook
7. Tetraspecific Antibodies Therapeutic Approaches
7.1 Tetraspecific Antibodies As Monotherapy
7.2 Tetraspecific Antibodies As Combinational Therapy
7.3 Tetraspecific Antibodies As Targeted Approach
8. Tetraspecific Antibodies Therapeutic Application In
9. Cancer
9.1 8.1 Overview
9.2 8.2 Ongoing Research and Development
10. Competitive Landscape
10.1 9.1 Innate Pharma
10.2 9.2 ModeX Therapeutics (OPKO Health)
10.3 9.3 Ruijin Hospital
10.4 9.4 Sichuan Baili Pharmaceutical
10.5 9.5 SystImmune
List of Figures & Tables
Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells and NK Cells In Close Proximity
Figure 3-1: Global - Tetraspecific Antibodies In Clinical Trials By Company, 2023
Figure 3-2: Global - Tetraspecific Antibodies In Clinical Trials By Country, 2023
Figure 3-3: Global - Tetraspecific Antibodies Clinical Trials By Indication, 2023
Figure 3-4: Global - Tetraspecific Antibodies In Clinical Trials By Phase, 2023
Figure 5-1: ANKETandreg; Platform - Innate Pharma
Figure 5-2: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 5-3: STEALTH - ModeX Therapeutics
Figure 5-4: MSTAR - ModeX Therapeutics
Figure 5-5: Features of MSTAR
Figure 5-6: MATCH - Numab
Figure 5-7: Features of BiXAb
Figure 5-8: Zyngenia Technology Approach
Figure 5-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 5-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 5-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 5-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 5-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 5-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 5-7: Novel Tetraspecific Format Developed By The Roche Pharma Research and Early Development
Figure 8-1: GNC-038 Phase I/II Study (NCT04606433) - Initiation and Completion Years
Figure 8-2: GNC-038 Phase I/II Study (NCT05192486) - Initiation and Completion Years
Figure 8-3: GNC-038 Phase I/II Study (NCT05485753) - Initiation and Completion Years
Figure 8-4: GNC-038 Phase I/II Study (NCT05623982) - Initiation and Completion Years
Figure 8-5: GNC-038 Phase I/II Study (NCT05627856) - Initiation and Completion Years
Figure 8-6: GNC-039 Phase I/II Study (NCT04794972) - Initiation and Completion Years
Figure 8-7: GNC-035 Phase I Study (NCT05039931) - Initiation and Completion Years
